01Overview 02Follow the Money 03Daily Brief 04Live 05Congress 06Corporate Insiders 07Government Money 08Political Influence 09Institutions 10Washington Network 11Follow the Power 12Disclosure Clock 13AI Investigator 14Watchlist

Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology Match review Launch readiness

Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…

Overview Follow the Money Daily Brief Live Congress Corporate Insiders Government Money Political Influence Institutions Washington Network Follow the Power Disclosure Clock AI Investigator Watchlist Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology Match review Launch readiness

01Overview 02Follow the Money 03Daily Brief 04Live 05Congress 06Corporate Insiders 07Government Money 08Political Influence 09Institutions 10Washington Network 11Follow the Power 12Disclosure Clock 13AI Investigator 14Watchlist

Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology Match review Launch readiness

Overview Follow the Money Daily Brief Live Congress Corporate Insiders Government Money Political Influence Institutions Washington Network Follow the Power Disclosure Clock AI Investigator Watchlist Convergence INSIDER Alpha Signal ledger Historical Replay Robinhood Chain Proof Trading Token Pro Account Methodology Match review Launch readiness

Data sources

SEC FORM 414m ago

HOUSE PTR14m ago

SEC 13F14m ago

ROBINHOOD CHAIN13m ago

Public company

RNAAtrium Therapeutics, Inc.

CIK 0002093101

EDGAR filings Open in network

Disclosed transactions0

Buys / sells0 / 0

Max Insider Score—

Connections2with evidence

RNA · disclosed activity on price

Disclosed transactions

No records

No transactions recorded for this profile.

Verified connections

In industryevidence
Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
← Lobbied forevidence
FEROX STRATEGIESLDA Q1 2026 first quarter · Health issues · Aug 26, 2026

Lobbying

$110K reported · de-duplicated

2026 Q2 $80K via firms2026 Q1 $30K via firms

FEROX STRATEGIES$30K2026 Q1 · posted Aug 26, 2026 · Health issues
FEROX STRATEGIES—2026 Q1 · posted Aug 26, 2026 · Health issues, Pharmacy
FEROX STRATEGIES$80K2026 Q2 · posted Aug 26, 2026 · Health issues

Connected PAC contributions

FEC · direct to members

No contributions from a PAC connected to this company.